Is Glycemic variability important to assessing antidiabetes therapies?

被引：10

作者：

Kovatchev B.P. ^{[1
]}

机构：

[1] University of Virginia Health System, Charlottesville, VA 22908

来源：

Current Diabetes Reports | 2006年 / 6卷 / 5期

基金：

美国国家卫生研究院;

关键词：

Hypoglycemia; Exenatide; Continuous Glucose Monitoring; Glycemic Variability; Pramlintide;

D O I：

10.1007/s11892-006-0005-z

中图分类号：

学科分类号：

摘要：

Traditionally, statistical estimation of glycemic variability includes computing standard deviation of glucose readings or related statistics (eg, M value, mean amplitude of glucose excursions, and so forth). We advocate an alternative approach using risk measures of variability, which have substantial clinical and numerical advantages. In addition, continuous glucose monitoring (CGM) data have clinically important inherent temporal structure that should be taken into consideration. Thus, temporal variability methods are discussed for the analysis and interpretation of CGM output. Copyright © 2006 by Current Science Inc.

引用

页码：350 / 356

页数：6

共 49 条

[1]

Svendsen P.A., Lauritzen T., Soegard U., Nerup J., Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes, Diabetologia, 23, pp. 403-405, (1982)

[2]

Santiago J.V., Lessons from the Diabetes Control and Complications Trial, Diabetes, 42, pp. 1549-1554, (1993)

[3]

The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus, N Engl J Med, 329, pp. 978-986, (1993)

[4]

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes, Lancet, 352, pp. 837-853, (1998)

[5]

The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial, Diabetes, 44, pp. 968-983, (1995)

[6]

Brownlee M., Hirsh I.B., Glycemic variability: A hemoglobin A1c-independent risk factor for diabetic complications?, JAMA, 295, pp. 1707-1708, (2006)

[7]

Diabetes, 46, pp. 271-286, (1997)

[8]

Henderson J.N., Allen K.V., Deary I.J., Frier B.M., Hypoglycemia in insulin-treated type 2 diabetes: Frequency, symptoms and impaired awareness, Diabet Med, 20, pp. 1016-1021, (2003)

[9]

Cryer P.E., Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: A vicious cycle, Diabetes, 41, pp. 255-260, (1992)

[10]

Segel S.A., Paramore D.S., Cryer P.E., Hypoglycemia-associated autonomic failure in advanced type 2 diabetes, Diabetes, 51, pp. 724-733, (2002)

← 1 2 3 4 5 →